Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy

Journal of Oncology Pharmacy Practice

Volumn 12, Issue 3, 2006, Pages 143-154

  Sommer, Abigail L ^a   Wachel, Brandi K ^a   Smith, Judith A ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Chemotherapy; Immunosuppression; Influenza; Vaccine

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; IFOSFAMIDE; INACTIVATED VACCINE; INFLUENZA VACCINE; IRINOTECAN; LIVE VACCINE; LOMUSTINE; MELPHALAN; MENINGOCOCCUS VACCINE; PLACEBO; PNEUMONVAX 23; POLIOMYELITIS VACCINE; POLYSACCHARIDE VACCINE; PROCARBAZINE; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; UNINDEXED DRUG; VACCINE;

ACTIVE IMMUNIZATION; ACUTE LYMPHOCYTIC LEUKEMIA; ANAPHYLAXIS; ANTIBODY RESPONSE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; B LYMPHOCYTE; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BREAST CANCER; BRONCHOSPASM; CANCER CHEMOTHERAPY; CELLULAR IMMUNITY; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; EDEMA; EGG ALLERGY; EVIDENCE BASED MEDICINE; FOOD DRUG INTERACTION; HEMAGGLUTINATION INHIBITION; HEMATOLOGIC MALIGNANCY; HEPATITIS; HIGH RISK PATIENT; HODGKIN DISEASE; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; INFECTION; INFECTION RISK; INFLUENZA; INFLUENZA VIRUS A; INJECTION SITE REACTION; INNATE IMMUNITY; LEUKEMIA REMISSION; LEUKOPENIA; LYMPHOCYTE DEPLETION; MALAISE; MEDLINE; MEMORY T LYMPHOCYTE; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL CHEMOTAXIS; POLIOMYELITIS; PRIORITY JOURNAL; REVACCINATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEPSIS; SOLID TUMOR; STREPTOCOCCUS INFECTION; SYSTEMATIC REVIEW; T LYMPHOCYTE; TIME;

ANTIBODY FORMATION; CANCER VACCINES; HUMANS; NEOPLASMS; VACCINATION;

EID: 33750742815     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155206070868     Document Type: Review

References (48)

1. Balmer CM, Valley AW, Iannucci A. Cancer treatment and chemotherapy. In Dipiro JT, Talbert RL, Yee GC, Matzhe GP, Well BG, Posey LM. eds. Pharmacotherapy. McGraw-Hill, 2005: 2279-328.
2. Perry M. Chemotherapy source book. Lippincott Williams & Wilkins, 2001.
3. Ozer H, Armitage JO, Bennett CL et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000; 18: 3558-85.
4. Beyer M, Kochanek M, Darabi, K. Reduced frequencies and suppressive function of CD4+CD25 high regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 2018-25.
5. Nowak A, Robinson BW, Lake RA et al. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 2002; 62: 2353-58.
6. Arnon R, Ben-Yedidia T. Old and new vaccine approaches. Int Immunopharmacol 2003; 3: 1195-204.
7. Ring A, Marx G, Steer C, et al. Poor uptake of influenza vaccinations in patients receiving cytotoxic chemotherapy. Int J Clin Pract 2003; 57: 542-43.
8. Earle CC. Influenza vaccination in elderly patients with advanced colorectal cancer. J Clin Oncol 2003; 21: 1161-66.
9. Arrowood JR, Hayney MS. Immunization recommendations for adults with cancer. Ann Pharmacother 2002; 36: 1219-29.
10. Anderson H, Petrie K, Berrisford C, et al. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer 1999; 80: 219-20.
11. Brydak LB, Guzy J, Starzyk J, et al. Humoral immune response after vaccination against influenza in patients with breast cancer. Support Care Cancer 2000; 9: 65-68.
12. Ganz PA, Shanley JD, Cherry JD. Response of patients with neoplastic diseases to influenza virus vaccine. Cancer 1978; 42: 2244-47.
13. Lange B, Shapiro SA, Waldman MTG, et al. Antibody responses to influenza immunization of children with acute lymphoblastic leukemia. J Infect Dis 1979; 140: 402-406.
14. Nordoy T, Aaberge IS, Husebekk A et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 2002; 19: 71-78.
15. Smithson WA, Siem RA, Ritts RE, et al. Response to influenza virus vaccine in children receiving chemotherapy for malignancy. J Pediatr 1978; 93: 632-34.
16. Sumaya CV, Williams TE, Brunell PA. Bivalent influenza vaccine in children with cancer. J Infect Dis 1977; 136: S656-60.
17. Allison JE, Glezen WP, Taber LD, et al. Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high-risk children. J Infect Dis 1977; 136: S672-76.
18. Borella L, Webster RG. The immunosuppressve effects of long-term combination chemotherapy in children with acute leukemia in remission. Cancer Res 1971; 31: 420-26.
19. Brown AE, Steinherz PG, Miller DR, et al. Immunization against influenza in children with cancer: results of a three-dose trial. J Infect Dis 1982; 145: 126.
20. Gross PA, Lee H, Wolff JA, et al. Influenza immunization in immunosuppressed children. J Pediatr 1978; 92: 30-35.
21. Hodges GR, Davis JW, Lewis HD Jr, et al. Response to influenza A vaccine among high-risk patients. South Med J 1979; 72: 29-32.
22. Ortbals DW, Liebhaber H, Presant CA, et al. Influenza immunization of adult patients with malignant diseases. Ann Intern Med 1977; 87: 552-57.
23. Robertson JD, Nagesh K, Jowitt SN et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 2000; 82: 1261-65.
24. Schafer AI, Churchill WH, Arnes P, et al. The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine. Cancer 1979; 43: 25-30.
25. Stiver HG, Weinerman BH. Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients. Can Med Assoc J 1978; 119: 733-38.
26. Ring A, Marx G, Steel C et al. Influenza vaccination and chemotherapy: a shot in the dark? Support Care Cancer 2002; 10: 462-465.
27. Gross PA, Gould L, Brown AE. Effect of Cancer Chemotherapy on the Immune Response to Influenza Virus Vaccine: Review of published studies. Reviews of Infectious Diseases 1985; 7: 613-618.
28. Ramanathan RK, Potter DM, Belani CP et al. Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients. J Clin Oncol 2002; 20: 4313-18.
29. Melcher L. Recommendations for influenza and pneumococcal vaccinations in people receiving chemotherapy. Clin Oncol 2005; 17: 12-15.
30. Molrine DC, George S, Tarbell N et al. Antibody responses to polysaccharide and polysaccharide conjugate vaccines after treatment of Hodgkin's Disease. Ann Intern Med 1995; 123: 828-34.
31. Hartkamp A, Mulder AHL, Rijkers GT, et al. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukemia. Vaccine 2001; 19: 1671-77.
32. Levine AM, Overturf GD, Field RF, et al. Use and efficacy of pneumococcal vaccine in patients with Hodgkin disease. Blood 1979; 54: 1171-75.
33. Siber GR, Weitzman SA, Aisenberg AC. Antibody response of patients with Hodgkin's Disease to protein and polysaccharide antigens. Rev Infect Dis 1981; 3: S144-59.
34. Siber GR, Gorham C, Martin P, et al. Antibody response to pretreatment immunization and post-treatment boosting with bacterial polysaccharide vaccines in patients with Hodgkin's Disease. Ann Intern Med 1986; 104: 467-75.
35. Atkinson WL, Pickering LK, Schwartz B, et al. General recommendations on immunization: recommendations of the advisory committee on immunization practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR 2002; 51: 1-36.
36. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR 1993; 42: 1-18.
37. Bilukka O, Rosenstein N. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005; 54: 1-21.
38. Torben EK, Mellander L, Hahn-Zoric M, et al. Intensive treatment for childhood acute lymphoblastic leukemia reduces immune responses to diphtheria, tetanus, and Haemophilus influenzae type B. J Pediatr Hematol Oncol 2004; 26: 727-34.
39. Rosen HR, Stierer M, Wolf HM, et al. Impaired primary antibody responses after vaccination against hepatitis B in patients with breast cancer. Breast Cancer Res Treat 1992; 23: 233-40.
40. Hovi L, Valle M, Siimes MA, et al. Impaired response to hepatitis B vaccine in children receiving anticancer chemotherapy. Pediatr Infect Dis J 1995; 14: 931-35.
41. Goyal S, Pai SK, Kelkar R, et al. Hepatitis B vaccination in acute lymphoblastic leukemia. Leuk Res 1998; 22: 193-95.
42. Weitberg AB, Weitzman SA, Watkins E, et al. Immunogenicity of hepatitis B vaccine in oncology patients receiving chemotherapy. J Clin Oncol 1985; 3: 718-22.
43. Locasciulli A, Santamaria M, Masera G, et al. Hepatitis B virus markers in children with acute leukemia: the effect of chemotherapy. J Med Virol 1985; 15: 29-33.
44. Zignol M, Peracchi M, Tridello G et al. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 2004; 101: 635-41.
45. Somjee S, Pai S, Kelkar R, et al. Hepatits B vaccination in children with acute lymphoblastic leukemia: results of an intensified immunization schedule. Leuk Res 1999; 23: 365-67.
46. Yetgin S, Tunc B, Koc A, et al. Two booster dose hepatitis B virus vaccination in patients with leukemia. Leuk Res 2001; 25: 647-49.
47. Ljungman P, Aschan J, Gustafsson B et al. Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients. Bone Marrow Transplant 2004; 34: 1067-69.
48. Bosu SK, Ciudad H, Sinks LF, et al. Antibody response to poliovirus immunization in childhood leukemia. Med Pediatr Oncol 1975; 1: 217-25.